CN102482265A - 用于治疗增殖性疾病的吡嗪基吡啶化合物 - Google Patents

用于治疗增殖性疾病的吡嗪基吡啶化合物 Download PDF

Info

Publication number
CN102482265A
CN102482265A CN2010800392830A CN201080039283A CN102482265A CN 102482265 A CN102482265 A CN 102482265A CN 2010800392830 A CN2010800392830 A CN 2010800392830A CN 201080039283 A CN201080039283 A CN 201080039283A CN 102482265 A CN102482265 A CN 102482265A
Authority
CN
China
Prior art keywords
alkyl
haloalkyl
branched
methyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800392830A
Other languages
English (en)
Chinese (zh)
Inventor
P·A·巴尔桑蒂
C·胡
K·B·菲斯特
M·森齐克
J·萨顿
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102482265A publication Critical patent/CN102482265A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2010800392830A 2009-09-04 2010-09-02 用于治疗增殖性疾病的吡嗪基吡啶化合物 Pending CN102482265A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US27593809P 2009-09-04 2009-09-04
US61/275,938 2009-09-04
US28496209P 2009-12-28 2009-12-28
US61/284,962 2009-12-28
PCT/EP2010/062881 WO2011026904A1 (en) 2009-09-04 2010-09-02 Pyrazinylpyridines useful for the treatment of proliferative diseases

Publications (1)

Publication Number Publication Date
CN102482265A true CN102482265A (zh) 2012-05-30

Family

ID=43480986

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800392830A Pending CN102482265A (zh) 2009-09-04 2010-09-02 用于治疗增殖性疾病的吡嗪基吡啶化合物

Country Status (10)

Country Link
US (1) US20120165306A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP2473505A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20120076352A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN102482265A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2010291199A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BR112012004836A2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2772265A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IN (1) IN2012DN01273A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2012002758A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2011026904A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795151A (zh) * 2014-08-06 2017-05-31 诺华股份有限公司 蛋白激酶c抑制剂和它们的使用方法
WO2021115335A1 (zh) * 2019-12-09 2021-06-17 石药集团中奇制药技术（石家庄）有限公司 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
CN115381823A (zh) * 2021-05-24 2022-11-25 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
CN115381824A (zh) * 2021-05-24 2022-11-25 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
CN115448874A (zh) * 2021-06-09 2022-12-09 石药集团中奇制药技术（石家庄）有限公司 固体形式的周期蛋白依赖性激酶9抑制剂及其用途

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8415381B2 (en) * 2009-07-30 2013-04-09 Novartis Ag Heteroaryl compounds and their uses
CN103339110A (zh) * 2011-01-28 2013-10-02 诺瓦提斯公司 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
WO2012101064A1 (en) * 2011-01-28 2012-08-02 Novartis Ag N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
WO2014106606A1 (en) * 2013-01-05 2014-07-10 F. Hoffmann-La Roche Ag Nove phenyl/pyridine series substitued by hydroxyethylamino for the treatment of cancer
WO2015037716A1 (ja) 2013-09-12 2015-03-19 住友化学株式会社 含窒素飽和複素環化合物
EP3804724B1 (en) 2016-10-20 2022-12-07 Pfizer Inc. Cdk inhibitors for treating pah
US12211592B2 (en) 2018-07-17 2025-01-28 Kuano Ltd. Machine learning based methods of analysing drug-like molecules
GB202013419D0 (en) 2020-08-27 2020-10-14 Kuano Ltd Transition state 2020

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
WO2002024681A2 (en) * 2000-09-20 2002-03-28 Ortho-Mcneil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
JP2010514689A (ja) * 2006-12-22 2010-05-06 ノバルティス アーゲー 癌、炎症およびウイルス感染症の処置のためのｃｄｋ阻害剤としてのヘテロアリール−ヘテロアリール化合物

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795151A (zh) * 2014-08-06 2017-05-31 诺华股份有限公司 蛋白激酶c抑制剂和它们的使用方法
US10508101B2 (en) 2014-08-06 2019-12-17 Novartis Ag Protein kinase C inhibitors and methods of their use
CN106795151B (zh) * 2014-08-06 2021-05-07 诺华股份有限公司 蛋白激酶c抑制剂和它们的使用方法
US11059804B2 (en) 2014-08-06 2021-07-13 Novartis Ag Protein kinase C inhibitors and methods of their use
US11505541B2 (en) 2014-08-06 2022-11-22 Novartis Ag Protein kinase C inhibitors and methods of their use
WO2021115335A1 (zh) * 2019-12-09 2021-06-17 石药集团中奇制药技术（石家庄）有限公司 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
CN114787142A (zh) * 2019-12-09 2022-07-22 石药集团中奇制药技术（石家庄）有限公司 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
CN114787142B (zh) * 2019-12-09 2024-08-02 石药集团中奇制药技术（石家庄）有限公司 作为周期蛋白依赖性激酶9抑制剂的化合物及其应用
CN115381824A (zh) * 2021-05-24 2022-11-25 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
WO2022247785A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
WO2022247796A1 (zh) * 2021-05-24 2022-12-01 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
CN115381823A (zh) * 2021-05-24 2022-11-25 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
CN115381824B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术（石家庄）有限公司 周期蛋白依赖性激酶9抑制剂的用途
CN115381823B (zh) * 2021-05-24 2024-11-05 石药集团中奇制药技术（石家庄）有限公司 一种周期蛋白依赖性激酶9抑制剂的用途
CN115448874A (zh) * 2021-06-09 2022-12-09 石药集团中奇制药技术（石家庄）有限公司 固体形式的周期蛋白依赖性激酶9抑制剂及其用途
WO2022257965A1 (zh) * 2021-06-09 2022-12-15 石药集团中奇制药技术（石家庄）有限公司 固体形式的周期蛋白依赖性激酶9抑制剂及其用途

Also Published As

Publication number Publication date
AU2010291199A1 (en) 2012-03-08
MX2012002758A (es) 2012-04-19
WO2011026904A1 (en) 2011-03-10
BR112012004836A2 (pt) 2019-09-24
EP2473505A1 (en) 2012-07-11
US20120165306A1 (en) 2012-06-28
KR20120076352A (ko) 2012-07-09
IN2012DN01273A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2015-05-15
CA2772265A1 (en) 2011-03-10

Similar Documents

Publication Publication Date Title
CN102498107A (zh) 作为激酶抑制剂的杂芳基化合物
CN102482265A (zh) 用于治疗增殖性疾病的吡嗪基吡啶化合物
CN102471310A (zh) 用于治疗增生性疾病的联吡啶化合物
TW202136241A (zh) 用作抗癌劑的吡唑基衍生物
TWI714590B (zh) 吡啶並［３，４－ｄ］嘧啶衍生物及其藥學上可被許可的鹽
CN103298787A (zh) 3-(氨基芳基)-吡啶化合物
CN102482218B (zh) 作为蛋白激酶调节剂的吡啶和吡嗪衍生物
CN114787159B (zh) Brm靶向化合物及相关使用方法
CN101889010B (zh) 异*唑-吡啶衍生物
CN104870448B (zh) 三唑并吡嗪
CN104169257B (zh) 用作smac模拟物的6‑炔基吡啶
TWI845638B (zh) Ｅｅｄ及ｐｒｃ２調節劑之巨環唑并吡啶衍生物
CN103221408A (zh) 三嗪-*二唑类化合物
CN103339110A (zh) 作为cdk9抑制剂的取代的杂-联芳基化合物及其用途
CN105209467A (zh) 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途
CN105408335A (zh) 吡唑并吡咯烷衍生物及其在治疗疾病中的用途
HK1209750A1 (en) Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
CN110256418A (zh) 1,3-噻唑-2-基取代的苯甲酰胺
WO2012101064A1 (en) N-acyl pyrimidine biaryl compounds as protein kinase inhibitors
CN107857755A (zh) 作为trka激酶抑制剂的n‑吡咯烷基、n`‑吡唑基‑脲、硫脲、胍和氰基胍化合物
WO2012101063A1 (en) N-acyl pyridine biaryl compounds and their uses
CN117986251A (zh) 4H-吡咯并[3,2-c]吡啶-4-酮化合物
HK1212699A1 (zh) 作为mknk1抑制剂的取代的咪唑并[1，2-b]哒嗪类化合物
CN102617548A (zh) 作为gpr受体激动剂的双环杂芳基化合物及其组合物和应用
CN109641871A (zh) 氨基吡啶衍生物及其作为选择性alk-2抑制剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120530